A controversial antidepressant, a drug for dementia & more: 4 recent FDA approvals

Four recent drugs or medical devices approved by the FDA since March 1:

1. Esketamine, which will be sold by Johnson & Johnson under the brand name Spravato, is a nasal spray to treat intractable depression. It is controversial due to its potential for abuse.

2. Rivastigmine Transdermal System was approved for the treatment of dementia associated with Alzheimer's and Parkinson's disease.

3. Imatinib Mesylate tablets, known by the brand name Stason, is a generic form of Novartis' Gleevec tablets. The chemotherapy drug slows the growth of cancer cells.

4. Glenmark Pharmaceuticals received final FDA approval for its generic version of Boehringer Ingelheim's Micardis HCT Tablets. The new generic, telmisartan and hydrochlorothiazide, treats high blood pressure.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars